Dishman Pharma surges over 7% as USFDA completes inspection for 2 sites

By: |
Published: July 14, 2016 4:21:28 PM

Dishman Pharmaceuticals and Chemicals Ltd surged over 7 per cent on Thursday after company's wholly owned subsidiary in Switzerland successfully completed USFDA inspection for two sites without any adverse observations.

 

India’s pharma exports grew from .66 billion to .54 billion in 2015 recording a growth of 7.55%. (Reuters)Dishman Pharmaceuticals and Chemicals Ltd surged over 7 per cent on Thursday after company?s wholly owned subsidiary in Switzerland successfully completed USFDA inspection for two sites without any adverse observations. (Photo: Reuters)

Dishman Pharmaceuticals and Chemicals Ltd surged over 7 per cent on Thursday after company’s wholly owned subsidiary in Switzerland successfully completed USFDA inspection for two sites without any adverse observations.

Share price of the company ended 2.66 per cent up at Rs 136.85. The scrip opened at Rs 132.05 and touched a high and low of Rs 143.40 and Rs 131.85, respectively.

“We are happy to inform that the Company’s wholly owned subsidiary, namely Carbogen Amcis AG., Switzerland, had successfully completed US FDA lnspection for its two sites located at Aarau and Neuland without any adverse observations and received the Establishment lnspection Report (ElR) for the same. Thus, now the company has the above two sites in addition to Bubendorf in Switzerland, which are approved by the USFDA,” the company said in a BSE filing.

It further added the company’s site at Naroda also successfully completed USFDA lnspection and received the Establishment lnspection Report (ElR) for the same.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition